Favipiravir
Medication
Favipiravir, sold under the brand name Avigan among others, is an antiviral medication used to treat influenza in Japan. It is also being studied to treat a number of other viral infections, including SARS-CoV-2. Like the experimental antiviral... Wikipedia
Formula: C5H4FN3O2
ATC code: J05AX27 (WHO)
ChemSpider: 431002
DrugBank: DB12466
Other names: T-705, favipira, favilavir
PubChem CID: 492405
Routes of administration: By mouth
People also ask
Did Favipiravir and Remdesivir get approved for treatment?
Is Favipiravir safe in children with COVID-19 and acute kidney injury?
Is remdesivir an antibiotic?
Is Molnupiravir still used?
Favipiravir: A new and emerging antiviral option in COVID-19 - NCBI
www.ncbi.nlm.nih.gov › PMC7467067
Sep 2, 2020 · Favipiravir is administered as a prodrug. It has an excellent bioavailability (∼94%), 54% protein binding, and a low volume of distribution (10 ...
Favipiravir is an antiviral used to manage influenza, and that has the potential to target other viral infections.
Favipiravir, sold under the brand name Avigan among others, is an antiviral medication used to treat influenza in Japan. It is also being studied to treat a ...
Dec 14, 2022 · The study showed that treatment with favipiravir did not improve prespecified clinical outcomes. However, post-hoc analyses suggested an earlier ...
May 26, 2021 · It has been approved for the treatment of new influenza viruses in Japan and China. It has also been shown to be effective against Ebola and RNA ...
It is an anti-viral agent that inhibits RNA-dependent RNA polymerase of several RNA viruses and is approved for the treatment of influenza in Japan. It has a ...
May 27, 2021 · Conclusions. Our study revealed that favipiravir can promote viral clearance within 7 days and clinical improvement within 14 days, especially ...
Favipiravir is a pyrazine carboxamide derivative developed by Toyama Chemical of Japan to act against many RNA viruses. It was first described as a selective ...
Jan 15, 2024 · Favipiravir, an anti-influenza drug, has in vitro antiviral activity against SARS-CoV-2. Clinical trial evidence to date is inconclusive.
It is a small molecule RdRp inhibitor that is a purine nucleotide analog. Inside the tissues, it undergoes phosphoribosylation to its active form, favipiravir– ...